Using targeted fecal microbiota transplantation to treat irritable bowel syndrome
Efficacy and Safety of Proteolytic Activity-Guided fecal Microbiota Transplantation for Irritable Bowel Syndrome (PRAGMAT trial)
This study is looking at whether a special treatment called fecal microbiota transplantation (FMT) can help people with irritable bowel syndrome (IBS) who started having symptoms after an intestinal infection, by using healthy gut bacteria from carefully chosen donors to improve their gut health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10773350 on NIH RePORTER |
What this research studies
This research investigates the use of fecal microbiota transplantation (FMT) to treat patients with irritable bowel syndrome (IBS), particularly those who developed symptoms after an intestinal infection. The study focuses on selecting donors with specific gut microbiota profiles that can help reduce harmful proteolytic activity in patients. By conducting a randomized, double-blind, placebo-controlled trial, the researchers aim to determine the safety and effectiveness of this targeted approach in alleviating IBS symptoms. Patients will receive FMT from carefully screened donors to potentially restore a healthier gut microbiome.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with post-infection irritable bowel syndrome.
Not a fit: Patients with IBS not related to prior intestinal infections or those with other gastrointestinal disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from post-infection irritable bowel syndrome.
How similar studies have performed: Previous studies have shown promising results with fecal microbiota transplantation in treating various gastrointestinal disorders, indicating potential success for this novel approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Grover, Madhusudan — Mayo Clinic Rochester
- Study coordinator: Grover, Madhusudan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.